Goldline Pharmaceutical promoter Swapan Khandelwal acquires 78,000 shares
- Swapan Khandelwal acquired 78,000 equity shares via open market on August 28, 2026
- Promoter stake increases to 30.08% from 29.27%
- Total holding now stands at 2,887,988 shares
- No encumbrances on the acquired or existing shares

*this image is generated using AI for illustrative purposes only.
Swapan Khandelwal, promoter and whole-time director of Goldline Pharmaceutical Limited , acquired 78,000 equity shares through an open market purchase on August 28, 2026.
The acquisition increases his total holding to 2,887,988 shares, representing 30.08% of the company’s total paid-up share capital. This marks a rise from his previous stake of 29.27% (2,809,988 shares).
Shareholding Details
The transaction was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing confirms that none of the acquired shares are encumbered by pledges or liens.
| Metric | Before Acquisition | After Acquisition |
|---|---|---|
| Shares Held | 2,809,988 | 2,887,988 |
| Stake Percentage | 29.27% | 30.08% |
| Encumbrances | Nil | Nil |
The company’s total equity share capital remains unchanged at 9,600,000 equity shares following the trade. There were no acquisitions or sales of warrants, convertible securities, or other instruments entitling the acquirer to voting rights during this period.
What the Numbers Show
The open market purchase indicates a consolidation of promoter interest without altering the company’s diluted share capital structure. With zero encumbrances reported both before and after the transaction, the promoter’s holding remains unpledged.
Historical Stock Returns for Goldline Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.14% | -0.46% | +6.85% | 0.0% | 0.0% | 0.0% |
How might this consolidation of promoter holding influence Goldline Pharmaceutical's stock price volatility in the near term?
Does this open market purchase signal confidence in upcoming quarterly earnings or a specific pipeline milestone for the company?
Could this move be a strategic step to prevent hostile takeovers or maintain control ahead of any potential board changes?






























